Ptc Therapeutics, INC Form 4 insider transactions

PTC Therapeutics' Chief Business Officer, Eric Pauwels, exercised stock options and subsequently sold the acquired shares, along with other common stock, under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Michael Schmertzler exercised 24,000 stock options at $30.86 per share, increasing his direct common stock holdings to 155,266 shares.

PTC Therapeutics Director Emma Reeve exercised stock options and sold an equal number of common shares under a pre-arranged 10b5-1 plan.

PTC Therapeutics CEO Matthew B. Klein reported the acquisition of restricted stock units and a subsequent sale to cover tax obligations.

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, exercised stock options and subsequently sold common stock totaling 71,928 shares under a pre-arranged 10b5-1 plan.

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, executed pre-planned sales of common stock totaling 35,572 shares on November 24, 2025, following option exercises.

PTC Therapeutics Director Allan Steven Jacobson executed pre-planned option exercises and subsequent sales of common stock shares on November 24 and 25, 2025.

PTC Therapeutics Director Emma Reeve exercised stock options and sold 10,000 shares of common stock for $79.50 per share under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Stephanie Okey reported a gift of 867 common shares to a charitable organization.

PTC Therapeutics' Executive VP and CLO, Mark Elliott Boulding, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Emma Reeve exercised stock options and immediately sold the acquired common stock on November 12, 2025, under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Emma Reeve executed a planned sale of common stock and exercised options on October 30, 2025, under a pre-arranged 10b5-1 plan.

A PTC Therapeutics executive exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 plan.

Emma Reeve, a Director at PTC Therapeutics, Inc., executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock on October 3, 2025.

PTC Therapeutics Director Allan Steven Jacobson exercised options and immediately sold 12,000 shares of common stock for $65.00 per share under a pre-arranged plan.

A PTC Therapeutics Executive VP and CLO exercised stock options and sold an equivalent number of shares under a pre-arranged 10b5-1 plan.

Neil Gregory Almstead, Chief Technical Ops Officer of PTC Therapeutics, executed transactions involving the sale and acquisition of common stock on October 3, 2025, according to a Form 4 filing.

PTC Therapeutics Director Emma Reeve executed a series of stock option exercises and subsequent sales of common stock totaling 15,705 shares under a Rule 10b5-1 plan on September 11, 2025.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and subsequently sold 47,249 shares of common stock for approximately $2.89 million.

PTC Therapeutics Director David P. Southwell exercised stock options and immediately sold 12,000 shares for a significant gain.

PTC Therapeutics' Chief Business Officer, Eric Pauwels, executed a series of stock option exercises and subsequent share sales totaling 39,850 shares under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Allan Steven Jacobson sold 1,667 shares of common stock for $50.15 per share on August 28, 2025, executed under a Rule 10b5-1 plan.

A PTC Therapeutics executive exercised stock options and immediately sold the acquired shares under a pre-arranged trading plan.

PTC Therapeutics CEO Matthew B. Klein acquired 75,000 shares through RSU vesting following a regulatory milestone, while selling 10,739 shares to cover tax obligations.

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, sold 2,516 shares of common stock at $49.46 per share to satisfy tax withholding obligations related to RSU vesting.

Mark Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and sold shares of common stock on May 15 and 16, 2025, according to a Form 4 filing with the SEC.

CEO Matthew Klein sold 2,804 shares of PTC Therapeutics stock to cover tax obligations related to RSU vesting.

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold 897 shares of common stock on April 2, 2025, to cover tax obligations related to vesting RSUs.

Eric Pauwels, Chief Business Officer of PTC Therapeutics, sold shares of common stock between March 14 and March 17, 2025, under a pre-arranged 10b5-1 trading plan.

Director Stephanie Okey sold 5,000 shares of PTC Therapeutics (PTCT) common stock at $54 per share on March 13, 2025.